BioInvent International AB (OSTO:BINV) Institutional Ownership : 13.76% (As of Jun. 29, 2025)

View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioInvent International AB's institutional ownership is 13.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioInvent International AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioInvent International AB's Float Percentage Of Total Shares Outstanding is 0.00%.

BioInvent International AB Institutional Ownership Historical Data

The historical data trend for BioInvent International AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Institutional Ownership Chart

BioInvent International AB Historical Data

The historical data trend for BioInvent International AB can be seen below:

	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-03-31	2025-04-30	2025-05-31
Institutional Ownership	13.53	13.54	14.31	14.35	14.23	13.41	13.36	13.35	13.32	13.76

BioInvent International AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

0H22:UK BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.